Literature DB >> 15718487

Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines.

Graeme Eisenhofer1, Jacques W M Lenders, David S Goldstein, Massimo Mannelli, Gyorgy Csako, McClellan M Walther, Frederieke M Brouwers, Karel Pacak.   

Abstract

BACKGROUND: Measurements of plasma free metanephrines (normetanephrine and metanephrine) provide a useful test for diagnosis of pheochromocytoma and may provide other information about the nature of these tumors.
METHODS: We examined relationships of tumor size, location, and catecholamine content with plasma and urinary metanephrines or catecholamines in 275 patients with pheochromocytoma. We then prospectively examined whether measurements of plasma free metanephrines could predict tumor size and location in an additional 16 patients.
RESULTS: Relative proportions of epinephrine and norepinephrine in tumor tissue were closely matched by relative increases of plasma or urinary metanephrine and normetanephrine, but not by epinephrine and norepinephrine. Tumor diameter showed strong positive relationships with summed plasma concentrations or urinary outputs of metanephrine and normetanephrine (r = 0.81 and 0.77; P <0.001), whereas relationships with plasma or urinary catecholamines were weaker (r = 0.41 and 0.44). All tumors in which increases in plasma metanephrine were >15% of the combined increases of normetanephrine and metanephrine either had adrenal locations or appeared to be recurrences of previously resected adrenal tumors. Measurements of plasma free metanephrines predicted tumor diameter to within a mean of 30% of actual diameter, and high plasma concentrations of free metanephrine relative to normetanephrine accurately predicted adrenal locations.
CONCLUSIONS: Measurements of plasma free metanephrines not only provide information about the likely presence or absence of a pheochromocytoma, but when a tumor is present, can also help predict tumor size and location. This additional information may be useful for clinical decision-making during tumor localization procedures.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15718487     DOI: 10.1373/clinchem.2004.045484

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  47 in total

1.  Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.

Authors:  Montserrat Ayala-Ramirez; Lei Feng; Mouhammed A Habra; Thereasa Rich; Paxton V Dickson; Nancy Perrier; Alexandria Phan; Steven Waguespack; Shreyaskumar Patel; Camilo Jimenez
Journal:  Cancer       Date:  2011-10-17       Impact factor: 6.860

2.  Case 2: Severe headache and paroxysmal seizures in a 14-year-old boy with cyclic vomiting syndrome.

Authors:  Yun-Jin Lee; Gyu Min Yeon; Young Mi Kim; Sang Ook Nam
Journal:  Paediatr Child Health       Date:  2015-03       Impact factor: 2.253

Review 3.  Current approaches and recent developments in the management of head and neck paragangliomas.

Authors:  David Taïeb; Alexandre Kaliski; Carsten C Boedeker; Victoria Martucci; Tito Fojo; John R Adler; Karel Pacak
Journal:  Endocr Rev       Date:  2014-07-17       Impact factor: 19.871

4.  Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma.

Authors:  Graeme Eisenhofer; Karel Pacak; Thanh-Truc Huynh; Nan Qin; Gennady Bratslavsky; W Marston Linehan; Massimo Mannelli; Peter Friberg; Stefan K Grebe; Henri J Timmers; Stefan R Bornstein; Jacques W M Lenders
Journal:  Endocr Relat Cancer       Date:  2010-12-21       Impact factor: 5.678

5.  Different expression of catecholamine transporters in phaeochromocytomas from patients with von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2.

Authors:  Thanh-Truc Huynh; Karel Pacak; Frederieke M Brouwers; Mones S Abu-Asab; Robert A Worrell; Macclellan M Walther; Abdel G Elkahloun; David S Goldstein; Susannah Cleary; Graeme Eisenhofer
Journal:  Eur J Endocrinol       Date:  2005-10       Impact factor: 6.664

Review 6.  Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.

Authors:  Graeme Eisenhofer; Arthur S Tischler; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

7.  Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.

Authors:  Susannah Cleary; Jacqueline K Phillips; Thanh-Truc Huynh; Karel Pacak; Abdel G Elkahloun; Jennifer Barb; Robert A Worrell; David S Goldstein; Graeme Eisenhofer
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

8.  Gender-related differences in the clinical presentation of malignant and benign pheochromocytoma.

Authors:  Edwin W Lai; Shiromi M Perera; Bas Havekes; Henri J L M Timmers; Frederieke M Brouwers; Beverly McElroy; Karen T Adams; Shoichiro Ohta; Robert A Wesley; Graeme Eisenhofer; Karel Pacak
Journal:  Endocrine       Date:  2008-11-04       Impact factor: 3.633

9.  Malignant paraganglioma associated with succinate dehydrogenase subunit B in an 8-year-old child: the age of first screening?

Authors:  Tamara Prodanov; Bas Havekes; Katherine L Nathanson; Karen T Adams; Karel Pacak
Journal:  Pediatr Nephrol       Date:  2009-02-03       Impact factor: 3.714

Review 10.  [Pheochromocytoma - still a challenge].

Authors:  N Reisch; M K Walz; Z Erlic; H P H Neumann
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.